The drugmaker's consolidated net profit surged 30% YoY to Rs 1,024 crore in the quarter ended Dec. 31, exceeding analysts' average estimate of Rs 885 crore, according to LSEG data. Revenue from operations rose 17% YoY to Rs 5,269 crore, driven by a 31% increase in its top market, the United States. However, growth in India slowed to 6.7% from 16% last year.
Comments
Post a Comment